Candidemia in the critically ill patient

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Mycology

Background:

• Invasive fungal infections (IFIs), particularly candidiasis, are increasingly prevalent in intensive care units (ICUs).
• Candida albicans remains common, but non-albicans Candida species are emerging, associated with greater mortality.
• Risk factors include compromised barriers, renal insufficiency, parenteral nutrition, and broad-spectrum antimicrobial or corticosteroid use.

Purpose of the Study:

• To review the current landscape of invasive candidiasis in ICUs.
• To highlight advances in diagnosis and treatment of IFIs.
• To evaluate the role of newer antifungal agents in critically ill patients.

Main Methods:

• Literature review of recent studies on invasive candidiasis in ICUs.
• Analysis of diagnostic methods, including biomarker detection (e.g., (1-->3)-beta-D-glucan) and predictive scores.
• Evaluation of current and emerging antifungal therapies, focusing on azoles and echinocandins.

Main Results:

• Non-albicans Candida species are associated with increased mortality compared to Candida albicans.
• Early detection of IFIs through biomarkers and predictive scores aids in reducing morbidity and mortality.
• Newer antifungal agents, particularly echinocandins, demonstrate favorable efficacy and safety profiles.

Conclusions:

• Echinocandins are the preferred treatment for invasive candidiasis in critically ill patients due to their efficacy and safety.
• Prompt diagnosis and appropriate antifungal selection are crucial for improving outcomes in ICU patients with IFIs.
• Continued surveillance and research into non-albicans Candida species and novel therapies are warranted.